Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER

AIMS: To assess fesoterodine 8 mg efficacy over time and vs. placebo in subjects with overactive bladder (OAB) who responded suboptimally to tolterodine extended release (ER) 4 mg. METHODS: In a 12-week, double-blind trial, subjects with self-reported OAB symptoms for ≥ 6 months, mean of ≥ 8 micturi...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Int J Clin Pract
Päätekijät: Kaplan, S A, Cardozo, L, Herschorn, S, Grenabo, L, Carlsson, M, Arumi, D, Crook, T J, Whelan, L, Scholfield, D, Ntanios, F
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BlackWell Publishing Ltd 2014
Aiheet:
Urology
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4265241/
https://ncbi.nlm.nih.gov/pubmed/24898471
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ijcp.12464
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia